Contrast-agent developer Amersham Health of the U.K. has received U.S. Food and Drug Administration approval for the manufacturing and packaging of its Omnipaque, Omniscan, and Visipaque products at its production facility in Cork, Ireland. Omnipaque is used for contrast x-ray exams, Omniscan is a general-purpose MRI agent, and Visipaque is a coronary x-ray contrast product.
By AuntMinnie.com staff writers
July 11, 2002
Related Reading
Amersham, Premier extend brachytherapy seed agreements, July 2, 2002
Amersham to market Optison in Europe, June 6, 2002
Amersham inks supply deal with Novation, May 29, 2002
Amersham shows uptick in Q1 numbers, April 29, 2002
Amersham launches online encyclopedia, March 4, 2002
Copyright © 2002 AuntMinnie.com
